

10th Annual New York Oncology Forum

Saturday, October 7, 2023, 8:00 am - 5:00 pm Sunday, October 8, 2023, 8:30 am - 12:00 pm

Sheraton LaGuardia East 135-20 39th Ave Flushing, NY 11354

Chinese American Hematologist & Oncologist Network (CAHON)

美国华裔血液及肿瘤专家学会

Conference Chairs

Delong Liu, MD, PhD – New York Medical College Yiwu Huang, MD, PhD – Maimonides Medical Center Bo Zhao, MD – Virginia Oncology Associates

Corporate Partners





Annual Supporters





Silver Sponsor





Bronze Sponsors









Exhibitors











































Visit the **AstraZeneca Booth**to learn more









SCAN TO DISCOVER MORE

CABOMETYXhcp.com

CONTENTS

Event Sponsors inside cover
About CAHON page 3
Upcoming CAHON Events page 3
Meeting Agenda page 4, 5 & 6
About Our Speakers page 7 & 8

ABOUT CAHON

Founded by Chinese American Hematologists and Oncologists in 2005, the primary missions of CAHON are to foster communications amongst Chinese American medical professionals for the delivery of highquality health care to patients with



neoplastic and hematological diseases, and to promote medical information exchange between the United States and China in the field of hematology and oncology. CAHON strives to serve as a bridge among its members and between Chinese and American Hematology-Oncology communities for medical and educational exchange.

THE STORY BEHIND THE LOGO

CAHON'S logo was designed by Drs. Weijing Sun, Ke Liu, and Jeffrey Ye, under the supervision of the CAHON Board. The design has the following elements and takes the following considerations:

- The overall shape represents the globe.
- The blue, white, red and yellow represent the colors of two nations' flags. China and the US.

- The yellow and red stripes above the blue, represent bridges. One of CAHON's key missions is to serve as a bridge between Chinese American Hematology-Oncology communities for medical and educational exchange.
- The white space is in the shape of a heart. The hearts of our members continue to drive our mission to provide high quality patient care to everyone.

CAHON MEMBERSHIP

By joining CAHON you will have access to:

- A growing network of Chinese American professionals working in your field;
- A private WeChat group where you can submit clinical questions to respected colleagues who are knowledgeable in specific areas of hematology and oncology;
- Reduced or waived registration fees for all CAHON events and meetings along with priority hotel reservations;
- Members-only section of the CAHON website featuring the member directory; and
- Travel award opportunities.

MEMBERSHIP CATEGORIES

Regular/Active Membership Associate Membership Allied Membership

Visit cahon.org/membership for more information on membership.

Save the Date!

WINTER SYMPOSIUM AND RECEPTION

December 9, 2023 University Club Atop Symphony Tower San Diego, CA

Held during the ASH annual meeting, the Winter Symposium will offer expert perspectives and practical insights on current advancements in a variety of cancer treatments, as well as foster collaboration and provide a forum for interaction and collaboration between hematologists and oncologists.





10th Annual New York Oncology Forum (NYOF) Agenda

Saturday, October 7, 2023, 8:00 am – 5:00 pm Sunday, October 8, 2023, 8:30 am – 12:00 pm Sheraton LaGuardia East Hotel, Flushing, NY

SATURDAY, OCTOBER 7, 2023

7, 2023
On-site Registration, Exhibitors Visitation
Breakfast Promotional Talk - Sponsored by Merck A First-line Treatment Option for Certain Patients with Advanced Esophageal or GEJ Cancer Speaker: Angela Alistar, MD – Atlantic Medical Group-Oncology, Morristown Medical Center Moderator: Minggui Pan, MD – Stanford University
Plenary Session I – Part I Session Chairs: Bo Zhao, MD, PhD - CAHON President, Virginia Oncology Associates Ruirong Yuan, MD, PhD - CAHON Board Chair, New Jersey VA Medical Center
Welcome Remarks Delong Liu, MD, PhD - New York Medical College
Introduction of Lifetime Achievement Award recipient Ruirong Yuan, MD, PhD - CAHON Board Chair, New Jersey VA Medical Center
Lifetime Achievement Award Lecture Delong Liu, MD, PhD - New York Medical College
New Agents and Regimens for AML Speaker: Joseph Jurcic, MD - Columbia University Moderator: Richard Lin, MD, PhD - MSKCC
Break and Visit Exhibitors
Plenary Session I – Part II Session Chair: Hong Zheng, MD, PhD – Penn State University
New Agents and Regimens for Gastric Cancer Speaker: Yelena Janjigian, MD - Memorial Sloan Kettering Cancer Center Moderator: Ping Gu, MD, PhD - Memorial Sloan Kettering Cancer Center
Novel Agents and Regimens for Mantle Cell Lymphoma Speaker: Michael Wang, MD - MD Anderson Cancer Center Moderator: Jia Ruan, MD, PhD - Weill Cornell Medical College
Lunch Promotional Talk - Sponsored by AstraZeneca A Treatment Option for Patients with Resectable NSCLC and Treatment of ES-SCLC Speaker: Yuanbin Chen, MD, PhD - Cancer & Hematology Centers of Western Michigan Moderator: Yue Zhang, MD, MPH - Virginia Oncology Associates
Break and Visit Exhibitors
Plenary Session II Session Chair: Liang Deng, MD, PhD - MSKCC
Novel Agents and Regimens for Lung Cancer Speaker: Vamsidhar Velcheti, MD - NYU Langone's Perlmutter Cancer Center Moderator: Zujun Li, MD - NYU Langone Health

10th Annual New York Oncology Forum (NYOF) Agenda

SATURDAY, OCTOBER 7, 2023, CONTINUED

2:00 – 2:40 pm New Agents and Regimens for Breast Cancer

Speaker: Cynthia Ma, MD, PhD. - Washington University School of Medicine St. Louis

Moderator: Yixing Jiang, MD, PhD - University of Maryland

2:40 – 3:00 pm **Break and Visit Exhibitors**

3:00- 3:40 pm Plenary Session III

Session Chair: Chong-xian Pan, MD, PhD - Harvard University

3:00- 3:40 pm New Agents and Regimens for GU Cancers

Speaker: Tian Zhang, MD - UT Southwestern Medical Center Moderator: Haoran Li, MD - University of Kansa Cancer Center

3:40 – 4:00 pm **Break and Visit Exhibitors**

4:00 – 5:00 pm Case Presentation - Clinical Hematology/Oncology Session

Session Chairs: David Chang, MD, PhD - Virginia Oncology Associates

Hongtao Liu, MD, PhD - University of Wisconsin

Case presenters:

Hematology case by Xiaoyang Wang, MD - Westchester Medical Center

Solid Tumor case by Ping Gu, MD, PhD - *Memorial Sloan Kettering Cancer Center*

Discussion Panel:

Zhengrui Xiao, MD - *Montefiore Medical Center*

Jeffrey Pu, MD, PhD – University of Arizona

Faye Yin, MD – RWJ University Hospital Somerset

Yong Ji, MD, PhD - Penn Medicine

Henry Xiong, MD, PhD - The Center for Cancer and Blood Disorders

William Li, MD - Queens Health Network

Peter Jiang, MD, PhD - John B. Amos Cancer Center, GA

Wendy Wang, MD - The Everett Clinic

Bill Gai, MD - LIFEBRIDGE Health

Chongze Ma, MD, PhD - Danbury Hospital, CT

Ligeng Tian, MD, PhD - Virginia Oncology Associates

Xiao Su, MD, PhD - Saratoga Hospital, NY

Meng Xu Welliver, MD, PhD – Mayo Clinic

Lan Mo, MD, PhD - Maimonides Medical Center

Shuang Fu, MD, PhD - Jackson Hematology Oncology

Qi Feng, MD, PhD - Brooklyn, NY

Songchuan Guo, MD, PhD - Brooklyn, NY

Zili He, MD, PhD - Flushing Hospital, NY

Xinhua Zhu, MD, PhD - Zuckerberg Cancer Center, NY

Spring Kong, MD, PhD - Hong Kong University

Haixia Qin, MD, PhD - MDACC at Cooper

6:00 – 10:00 pm Members Only Meeting and Reception

10th Annual New York Oncology Forum (NYOF) Agenda

SUNDAY, OCTOBER 8, 2023

8:00 – 9:30 am On-site Registration, Exhibitors Visitation

8:30 – 9:30 am **Breakfast Promotional Talk** - *Sponsored by Genentech*

Advancement in the 1L Treatment of Unresectable or Metastatic HCC

Speaker: Minsig Choi, MD - St. Elizabeth Healthcare

Moderator: Jingsong Zhang, MD, PhD - Lee Moffitt Cancer Center, FL

9:30 am – 12:00 pm Plenary Session IV

Session Chair: Hui Chen, MD, PhD - Duke University

9:30 – 10:00 am **Travel Grant Awardee Introduction**

Session Chairs: J. Christine Ye, MD, PhD - MD Anderson Cancer Institute

Zihai Li, MD, PhD - Ohio State University

Jeffrey Ye, MD, PhD - CAHON

Richard Xu, MD, PhD - Long Island Oncology

10:00 – 10:20 am **Break and Visit Exhibitors**

10:20 – 11:00 am Clinical development of CAR-T, ADC and BITE: Challenges and Solutions

Moderator: Sen Zhuang, MD, PhD – Janssen

Discussion panel:

Jingzhou Hou, MD, PhD - University of Pittsburgh Medical Center

Hongtao Liu, MD, PhD - University of Chicago

Richard Lin, MD, PhD - Memorial Sloan Kettering Cancer Center

Shenhong Wu, MD, PhD - Stony Brook University Tong Dai, MD, PhD - Westchester Medical Center Lei Zheng, MD, PhD, Johns Hopkins University

11:00 am- 12:00 pm Bridging Clinical Trial Collaboration

Moderators: Wenru Song, MD, PhD - Kira Pharmaceutical

Ke Liu, MD, PhD - Marengo Therapeutics

Discussion panel:

Yuxia Jia, MD, PhD - CAHON Max Ning, MD, PhD - CAHON

Kai He, MD, PhD - Ohio State University

Siwen Hu-Lieskovan, MD, PhD - University of Utah

Tianhong Li, MD, PhD - UC Davis

Weijing Sun, MD - *University of Kansas Medical Center*

Cynthia Taub, MD, MBA - SUNY Upstate David Liu, MD, PhD – CMO at Nuvation Li Xu, MD, FACOG - Transcenta Holding

Jianda Yuan, MD, PhD – Merck

12:00 pm Closing Remarks

Yiwu Huang, MD, PhD - Maimonides Medical Center

Speakers



Dr. Yelena Y. Janjigian is an Associate Professor and Chief of Gastrointestinal (GI) Oncology Service in the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSK). Her research career and clinical practice are focused on improving treatment outcomes for

patients with GI malignancies. She is an international expert in the management of cancers of the esophagus and stomach and has led several seminal studies that changed practice and set the standard of care for these diseases. She produced high impact publications describing the genomic basis for esophagogastric cancer pathogenesis and secured federal grants to fund future studies. Her research is focused on developing new treatments, with a special emphasis on defining the therapeutically relevant molecular characteristics of tumors in the GI tract, with 120 peer-reviewed publications to date.

Dr. Janjigian received her BS from the University of California, San Diego, and her MD from the New York University School of Medicine. She did her internal medicine residency at New York School of Medicine/Bellevue Hospital and her hematology/oncology fellowship training at MSKCC. She joined the MSK faculty in 2009 as a member of the GI Oncology Service.

Dr. Janjigian is an active member of American Society of Clinical Oncology (ASCO), American Association of Cancer Research (AACR) and European Society for Medical Oncology (ESMO) holding an array of leadership positions. As Chief of the GI Oncology Service, Dr. Janjigian's mission is to foster research and innovation that transforms the future of GI oncology to help patients worldwide.



Dr. Joseph Jurcic is Professor of Medicine at Columbia University Medical Center and Director of the Hematologic Malignancies Section of the Division of Hematology/Oncology. His main focus is the treatment of acute and chronic leukemias, myeloproliferative neoplasms, and

myelodysplastic syndrome. Research interests include acute myeloid leukemia, radioimmunotherapy with alpha and beta particle-emitting radioisotopes, monoclonal antibody therapy for leukemia, the development of novel small molecule inhibitors for leukemia, and the molecular monitoring of minimal residual disease.

He is the 2001 recipient of the Louis and Allston Boyer Young Investigator Award for Distinguished Achievement in Biomedical Research from Memorial Sloan-Kettering Cancer Center. He is author or coauthor of more than 80 articles and book chapters, has been the principal investigator on over 25 clinical trials, and regularly lectures at national and international meetings. He serves as a Leukemia Section Editor for The Oncologist. Prior to joining the faculty at Columbia University Medical Center, he was an Attending Physician on the Leukemia Service at Memorial Sloan-Kettering Cancer Center for over 18 years.



Dr. Cynthia Ma is a breast oncologist and a physician scientist, with research focuses on endocrine therapy and targeted agents for the treatment of breast cancer. She has led several biomarker directed, investigator initiated trials including neoadjuvant studies of endocrine

agents in combination with inhibitors against PI3K pathway or the CDK4/6 in patients with locally advanced estrogen receptor positive breast cancer. She is the study chair for the ongoing ALLIANCE ALTERNATE trial, which evaluates Ki67 based biomarkers as well as genomic predictors of endocrine responsiveness. She is the clinical director of the Breast Cancer Program in Medical Oncology at Washington University School of Medicine and a member of the Alliance Breast Committee.



Dr. Vamsidhar Velcheti is director of thoracic medical oncology at NYU Langone's Perlmutter Cancer Center, Dr. Velcheti specializes in treating patients who have thoracic malignancies, such as lung cancer and mesothelioma. The team at Perlmutter Cancer Center offers patients the most

advanced treatments, including immunotherapy and targeted therapy, and develops novel therapies through clinical trials.

For Dr. Velcheti, conquering cancer means offering people hope and giving them new opportunities. Dr. Velcheti states, "It's an incredible feeling to be part of a team that can make a difference in someone's life. Over the last few years, we have seen a paradigm shift in our understanding of the biology of cancer. We are able to deliver personalized treatments for patients based on a better understanding of the genetic makeup of the patient's tumor, which offers an improved chance of success. But I believe personalized medicine goes beyond just providing customized treatment plans—it involves understanding that patients may have varying physical, cognitive, and social needs. To meet every person's unique needs and provide the best patient experience, it is important to consider the patient and caregiver's circumstances as they cope with the diagnosis and begin treatment."

His research focuses on developing novel treatments called immunotherapy that can empower the patient's immune system to fight cancer and discovering biomarkers to predict which patients could benefit from immunotherapy. He has lectured at national and international meetings and have been the recipient of several awards by the American Society of Clinical Oncology, including the Young Investigator Award in 2012, the Merit Award in 2013, and the Career Development Award in 2015.

Speakers



Dr. Michael Wang is Professor in the Department of Lymphoma and Myeloma at MD Anderson Cancer Center. He has published more than 270 peer-reviewed papers and has presented his work at meetings nationally and internationally. He is the Director of the Mantle Cell Lymphoma (MCL)

Program of Excellence, Co-Director of Clinical Trials, and PI of the B-cell Lymphoma Moon Shot Program at MD Anderson. During the past 22 years, he has focused on both preclinical and clinical research. He established the first human primary MCL animal model for the study of the biology and treatment of MCL. He pioneered work to improve the treatment of patients with MCL, including the introduction of BTK inhibitors such as ibrutinib, acalabrutinib, and pirtobrutinib in the treatment algorithm, and has performed extensive work with CAR-T cells for the treatment of patients who relapsed on other therapies. His work has been published in the most prestigious medical journals, such as the New England Journal of Medicine and The Lancet.



Dr. Tian Zhang received her MD from the Harvard-MIT Health Sciences and Technology (HST) program and completed post-graduate training at Duke University, where she remained on faculty until 2021. She is currently Associate Professor within the Division of Hematology and

Oncology and Department of Internal Medicine at University of Texas Southwestern Medical Center, Harold C. Simmons Comprehensive Cancer Center. She leads the multi-disease and precision oncology program within the cancer center. Clinically she specializes in genitourinary malignancies. She participates actively in the cooperative group setting and currently serves as co-chair of the NCI GU Steering Committee Renal Task Force. She is a clinical researcher focused on improving novel therapies and biomarkers for patients with renal, prostate, and urothelial cancers.

<u> </u>	Notes



Visit booth 17 to explore the clinical profile of LIBTAYO across multiple indications

Visit booth 17 for information, or visit LIBTAYOhcp.com

REGENERON®

© 2022 Regeneron Pharmaceuticals, Inc. All rights reserved. LIB.22.11.0114 12/22

Summit Therapeutics is Enrolling Two Phase 3 Studies with Ivonescimab in NSCLC








Summit & Akeso's Strategic Partnership with an Aligned Mission Bringing Ivonescimab to Patients in Need*



To date: 825+ patients treated with ivonescimab in clinical trials in China and Australia. Summit will enroll over 400 patients total in the U.S., Canada and Europe



Ivonescimab simultaneously engages PD-1 & VEGF through cooperative binding

Ivonescimab is an investigational therapy that is not approved by any regulatory authority.

*Summit license territories: United States, Canada, Europe & Japan / Akeso: China & non-Summit territories.

Ivonescimab is currently being investigated in Phase 3 clinical studies. Phase 1 and 2 data generated and analyzed by Akeso.

NSCLC: Non-small Cell Lung Cancer



Harmon₁









GenentechA Member of the Roche Group

THEIR FIGHT. OUR MISSION.

Pioneering together for a cancer-free tomorrow.

gene.com





See the latest data for **SARCLISA + Kd**

Explore the full results of the IKEMA phase 3 trial at sarclisahcp.com



Kd=Kyprolis (carfilzomib) and dexamethasone

NOW APPROVED IN A 4TH INDICATION

EVENMORE PATIENTS MAY BE RIGHT BRUKINSA



REVIEW THE TRIALS SUPPORTING THE LATEST APPROVAL

BeiGene and BRUKINSA are registered trademarks owned by BeiGene, Ltd. or its affiliates. © BeiGene, Ltd. 2023 All Rights Reserved. 0522-BRU-PRC-038 1/2023





EXPLORE MORE AT HIDDENEGFRTHREATS.COM

*Common mutations include L858R and exon 19 deletions.10

EGFR, epidermal growth factor receptor; mNSCLC, metastatic non-small cell lung cancer

References: 1. Chiang AC, Fernandes AW, Pavilack M, et al. EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors. BMC Cancer. 2020;20(1):356. 2. Robichaux JP, Elaminy TY, Tan Z. et al. Mechanisms and clinical activity of an EGFR and HERs exon 20-selective kinase inhibitor in non-small cell lung cancer. Nat Med. 2018;24(5):638-646. 3. Riess JW, Gandara DR, Frampton GM, et al. Diverse EGFR Exon 20 insertions and co-occurring molecular alterations identified by comprehensive genomic profiling of NSCLC. J Thorac Oncol. 2018;13(10):1560-1568. 4. Arcila ME, Nafa K, Chaft JE, et al. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J Thorac Oncol. 2018;8(2):179-184. 6. Naidoo J, Sima C, Rodriguez K, et al. Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: clinical outcomes not erotherible. Cancer. 2015;21(18):3212-3220. 7. Chen D. Song Z, Cheng G. Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations. Onco Targets Ther. 2016;94:181-4186. 8. Bazhenova L, Minchom A, Viter S, et al. Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutation sand common EGFR mutations. Lung Cancer. 2021;16(1):19-19-19. Simchom A, et al. Underdiagnosis of EGFR exon 20 insertion mutation variants: estimates from NGS-based real-world datasets. Presented at the IASLC 2020 World Conference on Lung Cancer. January 28-31. 2021. Singapore. 10. Burnett H, Emich H, Carroll C, Stapleton N, Mahadevia P, Li T. Epidemiological and clinical burden of EGFR exon 20 insertion in advanced non-small-cell lung cancer a systematic literature review. PLoS One. 2021;16(3):e0247620. 11. Lin J, Li M, Chen S, Weng L, He Z. Efficacy and safety of first-generation EGFR-TKIs combined with chemotherapy for tre





Chinese American Hematologist and Oncologist Network (CAHON)

555 East Wells Street, Suite 1100 • Milwaukee, WI 53202 USA
Phone: 1 414-918-9890 • Fax: 1 414-276-3349